Peptide Tools for Advancing HIV Vaccine Research

HIV

About Human Immunodeficiency Virus

HIV in Research

JPT's HIV Peptide Tools

Filter products

B-cell Immunity

Drug delivery

T-cell immunity

Antigen Peptides

Cell-Penetrating Peptides

PepMix Peptide Pools

PepMix Peptide Pools Infections

PepMix Ultra Peptide Pools

PepStar Peptide Microarrays

AIDS (HIV)

Breast cancer

Cancer

Gene therapy

HIV

Infection

Sequence diversity

Artificial

Human

Human immunodeficiency virus (HIV)

CPP

Con B gag motif

Envelope glycoprotein

Envelope protein

Focal adhesion kinase 1

Gag polyprotein (gag)

Nef protein (NEF)

Pol polyprotein (POL)

No

D-TAT (47-57) - HIV transactivator

US$431.60

HIV 1 group M subtype B (isolate BH10) gp160 311-320, RGPGRAFVTI

US$533.00

HIV 1 group M subtype B (isolate BH10) gp160 314-322, GRAFVTIGK

HIV 1 group M subtype B (isolate BH8) Protein Nef 128-137, TPGPGVRYPL

US$178.10

HIV 1 group M subtype B (isolate PCV12) Protein Nef 134-141, RYPLTFGW

HIV 1 group M subtype B (isolate PCV12) Protein Nef 73-82, QVPLRPMTYK

HIV 1 group M subtype C (isolate 92BR025) Gag 178-185, TPQDLNTML

HIV 1 group M subtype H (isolate 90CF056) Gag 151-159, TLNAWVKVV

HIV 1 group M subtype H (isolate 90CF056) Gag 20-28, RLRPGGKKK

HIV 1 group M subtype H (isolate 90CF056) Gag-Pol polyprotein 745-753, AIFQSSMTK

Cellular Immune Response

Antigen specific stimulation of T cells

Immune monitoring of high-risk patients

Qualification of immunodominant antigens

Validating clinical T cell assays

PepMix HIV-1 Ultra Pools: specialist peptide pools reflecting sequence variety through either Envelope (ENV) protein, GAG poly protein, POL polyprotein, or NEF proteins

Custom PepMix Peptide Pools tailored to your specific needs

T cell assays in high-throughput T cell epitope discovery

Monitoring of cellular immune response

Clinical Trials

Humoral Immune Response

Immune monitoring of humoral responses

Profiling of HIV specific samples or antibodies

Evaluation of co-infection

Detection of epitopes and epitope spreading

PepStar Antigen Collection HIV Ultra for various HI-virus antigens

Custom PepStar Peptide Microarrays: you define content and layout

Clinical Peptides

References

OC18 Assessment of the specific cellular immune response to the recombinant herpes zoster vaccine in people living with HIVAlessio et al., Sex Trans Infect (2025) Product used: PepMix™ HIV-1 (POL) Ultra

Early Combination Antiretroviral Therapy Initiation During Primary HIV Infection Restricts HIV Reservoirs and Gut-Driven Inflammation but Fails to Rewire the Systemic Cytokine LandscapeBono et al., Open Forum Infectious Diseases (2026) - PMID: 41846601Product used: PepMix™ HIV (GAG) Ultra

Sustained HIV-1 remission after heterozygous CCR5Δ32 stem cell transplantationGaebler et al., Nature (2025) Products used: PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HHV6 (U90)

CD27 agonism enhances long-lived CD4 T cell vaccine responses critical for antitumor immunity Hwang et al., Science Immunology (2025) - PMID: 41417923 Products used: PepMix™ Human (ErbB2_ECD), PepMix™ Human (ErbB2_ICD), PepMix™ HIV-1 (GAG) Ultra, Custom pepMix LacZ

UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunityLaheurte et al., Cell Reports Medicine (2025) - PMID: 40543509 Products used: PepMix™ Human (NY-ESO-1), PepMix™ HIV-1 (ENV) Ultra

CD24-Fc resolves inflammation and enhances anti-HIV CD8 T cells with polyfunctionality during HIV-1 infection under ART Li et al., PLOS Pathogens (2025) - PMID: 40779581Product used: PepMix™ HIV-1 (GAG) Ultra

Depletion of plasmacytoid dendritic cells rescues HIV-reactive stem-like CD8+ T cells during chronic HIV-1 infectionLi et al., Science Translational Medicine (2025) Products used: PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (Con B gag motif)

Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b studyRamgopal et al., Nature Medicine (2025) Products used: PepMix™ HIV-1 (GAG) Ultra

Ultra-low level HIV p24 drives immune activation in antiretroviral therapy-treated people living with HIVRichter et al., Communications Medicine (2025) - PMID: 41331331Product used: PepMix™ HIV-1 (GAG) Ultra

Autologous HIV-specific T cell therapy targeting conserved epitopes is welltolerated in six adults with HIV: an openlabel, single-arm phase 1 study Sohai et al., Nature Communications (2025)Products used: PepMix™ Human (Actin), PepMix™ HIV-1 (NEF) Ultra, PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra

Cognate antigen engagement induces HIV-1 expression in latently infected CD4+ T cells from people on long-term antiretroviral therapyMoskovljevi e al., Immunity (2024) - PMID: 39612916Product used: PepMix™ HIV-1 (Con B gag motif)

Deciphering long-term immune effects of HIV-1/SARS-CoV-2 co-infection: a longitudinal studyVazquez-Alejo et al., Medical Microbiology & Immunology (2024) Product used: PepMix™ HIV-1 (GAG) Ultra

Vaccine responses and hybrid immunity in people living with HIV after SARS-CoV-2 breakthrough infectionsAlirezaylavasani et al., NPJ Vaccines (2024) - PMID: 39384763Product used: PepMix™ HIV-1 (GAG) Ultra

Enhanced detection of antigen-specific T cells by a multiplexed AIM assayLemieux et al., Cell Rep Methods (2024) - PMID: 38228152Products used: PepMix™ SARS-CoV-2 (Spike Glycoprotein), PepMix™ HIV-1 (GAG) Ultra, PepMix™ HIV-1 (POL) Ultra, PepMix™ HIV-1 (ENV) Ultra, PepMix™ HIV-1 (NEF) Ultra, PepMix™ CMVA (pp65)

Cognate Antigen Engagement induces HIV-1 Expression in CD4+ T cells from people in long-term Art Moskovljevic et al., BioRxiv (2024) Product used: PepMix HIV-1 (GAG) Ultra

Impaired T and "memory-like" NK-cell reconstitution is linked to late-onset HCMV reactivation after letermovir cessationLauruschkat et al., Blood Advances (2024) - PMID: 38315873Products used: PepMix™ HCMVA (pp65), PepMix™ HIV-1 (NEF) Ultra

Integrating Machine Learning-Enhanced Immunopeptidomics and SARS-CoV-2 PopulationScale Analyses Unveils Novel Antigenic Features for Next-Generation COVID-19 Vaccines Caron et al., Research Square (2024) Product used: PepMix™ HIV-1 (POL) Ultra

Vaccines targeting ESR1 activating mutations elicit anti-tumor immune responses and suppress estrogen signaling in therapy resistant ER+ breast cancer Dailey et al., Human Vaccines & Immunotherapeutics (2024) - PMID: 38330990 Products used: Custom PepMix (ESR1), PepMix™ HIV-1 (GAG) Ultra

Mosaic HIV-1 vaccine and SHIV challenge strain V2 loop sequence identity and protection in primatesVanshylla et al., NPJ Vacccines (2024) Products used: PepStar™ HIV-1 env (gp41), Custom PepStar for HIV1 pol & gag

Viral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall responseWilliams et al., PLOS Pathogens (2023) - PMID: 37256916Products used: custom PepStar & PepStar HIV-1 env (gp120 protein + signal peptide)

Ablative radiation alone in stage I lung cancer produces an adaptive systemic immune response: insights from a prospective studyVoong et al., Journal for ImmunoTherapy of Cancer (2023) Products used: CEFX Ultra SuperStim Pool MHC-II Subset & PepMix™ HIV-1 (GAG) Ultra

A cell-free antigen processing system informs HIV-1 epitope selection and vaccine designSengupta et al., Journal of Experimental Medicine (2023) - PMID: 37058141Products used: PepMix HIV-1 (NEF) Ultra, HIV-1 (Con B gag motif)

Lymph node dendritic cells harbor inducible replication-competent HIV despite years of suppressive ARTBanga et al., Cell Host & Microbe (2023) - PMID: 37751747

Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu et al., Cell Report (2022) - PMID: 34986348 Products used: PepMix HIV ENV Ultra

UltraNatural Immunity against HIV-1: Progression of Understanding after Association Studies Ma Luo, Viruses (2022) Product used: PepMix HIV-1 GAG Ultra

Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunityRosás-Umbert et al., Nature Communications (2022Products used: PepMix HIV-1 (GAG) Ultra, HIV-1 (ENV) Ultra, HIV-1 (NEF) Ultra, HIV-1 (POL) Ultra

Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b/2a, randomized trialGunst et al., Nature Medicine (2022)Product used: PepMix HIV Gag Ultra

Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHVWang et al., Vaccines (2022)Products used: PepStar™ HIV-1 env

Differential localization and limited cytotoxic potential of duodenal CD8+ T cellsMvaya et al., JCI Insight (2022) - PMID: 35132966Products used: PepMix™ HIV-1 (POL), HIV-1 (GAG) & HIV-1 (NEF)

Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunityShinya Abe et al., Immunotherapy of Cancer (2022)Products used: PepMix™ HIV-1 (GAG) Ultra

Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeysAmarendra Pegu et al., Cell Report (2022) - PMID: 34986348Products used: PepMix™ HIV-1 (ENV) Ultra

Lipid Nanoparticle Encapsulated Nucleoside-Modified mRNA Vaccines Elicit Polyfunctional HIV-1 Antibodies Comparable to Proteins in Nonhuman PrimatesKevin O. Saunders et al., BioRxiv, (2021)

Lipid Nanoparticle Encapsulated Nucleoside-Modified mRNA Vaccines Elicit Polyfunctional HIV-1 Antibodies Comparable to Proteins in Nonhuman PrimatesSamuel L. Vidal et al., Nature, (2021)

HIV-Specific T Cell Responses Reflect Substantive in Vivo Interactions With Antigen Despite Long-Term TherapyEva. M Stevenson et al., JCI Insight (2021)

Comparison of Shortened Mosaic HIV-1 Vaccine Schedules: a Randomised, Double-Blind, Placebo-Controlled Phase 1 Trial (IPCAVD010/HPX1002) And a Preclinical Study in Rhesus Monkeys (NHP 17–22)Kathryn E. Stephenson et al., The Lancet HIV (2020) - PMID: 32078815

Evaluation of HIV-1 Neutralizing and Binding Antibodies in Maternal-Infant Transmission in ThailandLindsay Wieczorek et al., Virology (2020) - PMID: n.a.

Antigen Responsive CD4+T Cell Clones Contribute to the HIV-1 Latent ReservoirPilar Mendoza et al., bioRxiv (2020) - PMID: n.a.

Enhancement of Immune Responses by Guanosine-Based Particles in DNA Plasmid Formulations against Infectious DiseasesSantos et al, Journal of Immunology Research (2019)

T-Cell Responses Targeting HIV Nef Uniquely Correlate With Infected Cell Frequencies After Long-Term Antiretroviral TherapyThomas et al, PLoS Pathogen(2019)

Envelope-Specific Epitope Recognition Patterns of HIV Vaccine-Induced IgG Antibodies are Linked to Immunogen Structure and SequenceNadai et al, Front. Immunol (2019)

Neutralizing Antibody Responses following Long-Term Vaccination with HIV-1 Env gp140 in Guinea PigsBricault et al, Journal of Virology (2018)

Cytomegalovirus-specific T-cells Are Associated with Immune Senescence, But Not With Systemic Inflammation, in People Living with HIVBallegaard et al, Sci Rep. (2018)

Differential Expression of CD8+ T Cell Cytotoxic Effector Molecules in Blood and Gastrointestinal Mucosa in HIV-1 InfectionKiniry et al, The Journal of Immunology (2018)

Testimonial

Application Notes